Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
- 1 May 2000
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (9) , 726-733
- https://doi.org/10.1038/sj.gt.3301160
Abstract
Dendritic cells (DCs) are highly efficient antigen-presenting cells capable of priming both cytotoxic and helper T cells in vivo. Recent studies have demonstrated the potential use of DCs that are modified to carry tumor-specific antigens in cancer vaccines. However, the optimal administration route of DC-based vaccines to generate the greatest anti-tumor effect remains to be determined. This study is aimed at comparing the levels of immune responses and anti-tumor effect generated through different administration routes of DC-based vaccination. We chose the E7 gene product of human papillomavirus (HPV) as the model antigen and generated a stable DC line (designated as DC-E7) that constitutively expresses the E7 gene. Among the three different routes of DC-E7 vaccine administration in a murine model, we found that intramuscular administration generated the greatest anti-tumor immunity compared with subcutaneous and intravenous routes of administration. Furthermore, intramuscular administration of DC-E7 elicited the highest levels of E7-specific antibody and greatest numbers of E7-specific CD4+ T helper and CD8+ T cell precursors. Our results indicate that the potency of DC-based vaccines depends on the specific route of administration and that intramuscular administration of E7-transfected DCs generates the most potent E7-specific anti-tumor immunity.Keywords
This publication has 28 references indexed in Scilit:
- Targeting Human Papillomavirus Type 16 E7 to the Endosomal/Lysosomal Compartment Enhances the Antitumor Immunity of DNA Vaccines against Murine Human Papillomavirus Type 16 E7-Expressing TumorsHuman Gene Therapy, 1999
- Genetically modified bone marrow‐derived dendritic cells expressing tumor‐associated viral or “self” antigens induce antitumor immunity in vivoEuropean Journal of Immunology, 1997
- Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor VaccinesThe International Journal of Cell Cloning, 1997
- Origin, maturation and antigen presenting function of dendritic cellsCurrent Opinion in Immunology, 1997
- New insights into the mobilization and phagocytic activity of dendritic cells.The Journal of Experimental Medicine, 1996
- MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activationCell, 1994
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells.The Journal of Experimental Medicine, 1989
- An improved method of electroporation for introducing biologically active foreign genes into cultured mammalian cellsExperimental Cell Research, 1988